Industry Bulletins | May 9, 2018
NeuroStar Advanced Therapy Reaches Monumental Milestone Of 1.7 Million Treatments In The U.S.
NeuroStar Advanced Therapy (NeuroStar), a leader in transcranial magnetic stimulation (TMS), recently announced it has delivered more than 1.7 million treatments. These treatments—which target individuals battling with depression—having been administered to about 50,000 adults in the United States, according to the company.
The health outcomes of these treatments were recently presented at the 2018 American Psychiatric Association Annual Meeting in New York, and touched on what the company plans to do in the future to continue revolutionizing TMS treatment. It is estimated that approximately 5.5 million U.S. adults treated with antidepressants for depression do . . .